Publisher： Bentham Science Publishers
E-ISSN： 1875-6360|6|4|305-308
ISSN： 1573-3971
Source： Current Rheumatology Reviews, Vol.6, Iss.4, 2010-11, pp. : 305-308
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
In the last years, several key-pathways for the aberrant activation of fibroblasts in SSc have been identified in pre-clinical studies. This review summarizes recently identified molecular targets for novel anti-fibrotic approaches in systemic sclerosis (SSc) and other fibrotic disorders. We will focus on pathways that can be targeted by drugs that are either already approved for other indications or that are currently evaluated in clinical trials.
Related content
Access to resources
Recommend
